Monograph Details
|
|
Musculoskeletal Disorders
> Muscle spasms
|
|
DANTRIUM |
| Manufacturer |
|
Procter & Gamble Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Muscle relaxant (local). |
| Generic Name |
|
Dantrolene sodium 25mg, 50mg, 100mg; caps. |
| Indications |
|
Chronic spasticity. |
| Children |
|
0.5mg/kg once daily for 7 days, then 0.5mg/kg 3 times daily for 7 days, then 1mg/kg 3 times daily for 7 days, then 2mg/kg 3 times daily; max 100mg 4 times daily. |
| Adults |
|
25 mg once daily for 7 days, then 25 mg 3 times daily for 7 days, then 50 mg 3 times daily for 7 days, then 100 mg 3 times daily; max 100mg 4 times daily. |
| Contraindications |
|
Beneficial spasticity. Active hepatic disease. Pregnancy. Nursing mothers. |
| Precautions |
|
Impaired hepatic, pulmonary or cardiac function. Discontinue if no improvement after 45 days of therapy. Children <5 years. Monitor liver function during long-term use (esp. if female or >35 years). |
| Interactions |
|
Estrogens may increase risk of hepatotoxicity. CNS depressants potentiated. Avoid concurrent verapamil (cardiovascular collapse). |
| Adverse Reactions |
|
Hepatotoxicity, hepatitis, drowsiness, photosensitivity, dizziness, diarrhea, urinary changes, tachycardia, seizures, depression, rash. |
| How Supplied |
25mg—100, 500
50mg, 100mg—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
